Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Identifier: https://openscience.ub.uni-mainz.de/handle/20.500.12030/5916

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: In: Cancer medicine. 10. 5. 2021. 1562. 1575. -

Event: Veröffentlichung

(where): Mainz

(who): Universitätsbibliothek der Johannes Gutenberg-Universität Mainz

(when): 2021

Creator: Krebs, Franziska K.
Trzeciak, Emily R.
Zimmer, Sophia
Özistanbullu, Deniz
Mitzel-Rink, Heidrun
Meissner, Markus
Grabbe, Stephan
Loquai, Carmen
Tüttenberg, Andrea

DOI: 10.25358/openscience-5907

Handle: https://openscience.ub.uni-mainz.de/handle/20.500.12030/5916

URN: urn:nbn:de:101:1-2022020313282609276891

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Krebs, Franziska K.
Trzeciak, Emily R.
Zimmer, Sophia
Özistanbullu, Deniz
Mitzel-Rink, Heidrun
Meissner, Markus
Grabbe, Stephan
Loquai, Carmen
Tüttenberg, Andrea
Universitätsbibliothek der Johannes Gutenberg-Universität Mainz

Time of origin

2021

Other Objects (12)

Gene signature from cutaneous autoimmune diseases provides potential immunotherapy-relevant biomarkers in melanoma

Aufsatzsammlung

Immunotherapy of malignant melanoma

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Cancer immunotherapy beyond immune checkpoint inhibitors

PANoptosis-related prognostic signature predicts overall survival of cutaneous melanoma and provides insights into immune infiltration landscape

Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors

Immune checkpoint inhibitors for multiple myeloma immunotherapy

Comprehensive analysis identifies IFI16 as a novel signature associated with overall survival and immune infiltration of skin cutaneous melanoma

Beyond PD-1 Immunotherapy in Malignant Melanoma

Advances in predictive biomarkers for melanoma immunotherapy

The age of enlightenment in melanoma immunotherapy

Gene signature from cutaneous autoimmune diseases provides potential immunotherapy-relevant biomarkers in melanoma

Aufsatzsammlung

Immunotherapy of malignant melanoma

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Cancer immunotherapy beyond immune checkpoint inhibitors

PANoptosis-related prognostic signature predicts overall survival of cutaneous melanoma and provides insights into immune infiltration landscape

Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors

Immune checkpoint inhibitors for multiple myeloma immunotherapy

Comprehensive analysis identifies IFI16 as a novel signature associated with overall survival and immune infiltration of skin cutaneous melanoma

Beyond PD-1 Immunotherapy in Malignant Melanoma

Advances in predictive biomarkers for melanoma immunotherapy

The age of enlightenment in melanoma immunotherapy

Gene signature from cutaneous autoimmune diseases provides potential immunotherapy-relevant biomarkers in melanoma

Aufsatzsammlung

Immunotherapy of malignant melanoma

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Cancer immunotherapy beyond immune checkpoint inhibitors

PANoptosis-related prognostic signature predicts overall survival of cutaneous melanoma and provides insights into immune infiltration landscape

Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors

Immune checkpoint inhibitors for multiple myeloma immunotherapy

Comprehensive analysis identifies IFI16 as a novel signature associated with overall survival and immune infiltration of skin cutaneous melanoma

Beyond PD-1 Immunotherapy in Malignant Melanoma

Advances in predictive biomarkers for melanoma immunotherapy

The age of enlightenment in melanoma immunotherapy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

Gene signature from cutaneous autoimmune diseases provides potential immunotherapy-relevant biomarkers in melanoma

Immunotherapy of malignant melanoma

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Cancer immunotherapy beyond immune checkpoint inhibitors

PANoptosis-related prognostic signature predicts overall survival of cutaneous melanoma and provides insights into immune infiltration landscape

Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors

Immune checkpoint inhibitors for multiple myeloma immunotherapy

Comprehensive analysis identifies IFI16 as a novel signature associated with overall survival and immune infiltration of skin cutaneous melanoma

Beyond PD-1 Immunotherapy in Malignant Melanoma

Advances in predictive biomarkers for melanoma immunotherapy

The age of enlightenment in melanoma immunotherapy

Gene signature from cutaneous autoimmune diseases provides potential immunotherapy-relevant biomarkers in melanoma

Immunotherapy of malignant melanoma

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Cancer immunotherapy beyond immune checkpoint inhibitors

PANoptosis-related prognostic signature predicts overall survival of cutaneous melanoma and provides insights into immune infiltration landscape

Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors

Immune checkpoint inhibitors for multiple myeloma immunotherapy

Comprehensive analysis identifies IFI16 as a novel signature associated with overall survival and immune infiltration of skin cutaneous melanoma

Beyond PD-1 Immunotherapy in Malignant Melanoma

Advances in predictive biomarkers for melanoma immunotherapy

The age of enlightenment in melanoma immunotherapy

Gene signature from cutaneous autoimmune diseases provides potential immunotherapy-relevant biomarkers in melanoma

Immunotherapy of malignant melanoma

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Cancer immunotherapy beyond immune checkpoint inhibitors

PANoptosis-related prognostic signature predicts overall survival of cutaneous melanoma and provides insights into immune infiltration landscape

Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors

Immune checkpoint inhibitors for multiple myeloma immunotherapy

Comprehensive analysis identifies IFI16 as a novel signature associated with overall survival and immune infiltration of skin cutaneous melanoma

Beyond PD-1 Immunotherapy in Malignant Melanoma

Advances in predictive biomarkers for melanoma immunotherapy

The age of enlightenment in melanoma immunotherapy

Related objects

Reset password